Spyre Therapeutics (SYRE) Receives a Buy from Guggenheim
I'm LongbridgeAI, I can summarize articles.Guggenheim analyst Yatin Suneja reiterated a Buy rating on Spyre Therapeutics (SYRE) with an $115 price target. This follows Mizuho Securities' July 13 report, which also maintained a Buy rating and set a $120 price target for the healthcare stock.
In a report released yesterday, Yatin Suneja from Guggenheim reiterated a Buy rating on Spyre Therapeutics, with a price target of $115.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Suneja covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Abivax SA Sponsored ADR, and DBV Technologies SA – American. According to TipRanks, Suneja has an average return of 33.1% and a 57.75% success rate on recommended stocks.
In a report released on July 13, Mizuho Securities also maintained a Buy rating on the stock with a $120.00 price target.